Title
Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive

Permalink
https://escholarship.org/uc/item/719981fv

Authors
Sasso, O
Wagner, K
Morisseau, C
et al.

Publication Date
2015-07-01

DOI
10.1016/j.phrs.2015.04.001

License
CC BY 4.0

Peer reviewed
Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive

Oscar Sasso\textsuperscript{a,}\textdagger, Karen Wagner\textsuperscript{b,‡}, Christophe Morisseau\textsuperscript{b}, Bora Inceoglu\textsuperscript{b}, Bruce D. Hammock\textsuperscript{b}, and Daniele Piomelli\textsuperscript{c}

\textsuperscript{a}Drug Discovery and Development, Istituto Italiano di Tecnologia, Via Morego, 30, Genova, Italy 16163
\textsuperscript{b}Department of Entomology and UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA, USA, 95616
\textsuperscript{c}Departments of Anatomy and Neurobiology, Pharmacology and Biological Chemistry, University of California, Irvine, USA, 92697-4621

Abstract

We need better medicines to control acute and chronic pain. Fatty acid amide hydrolase (FAAH) and soluble epoxide hydrolase (sEH) catalyze the deactivating hydrolysis of two classes of bioactive lipid mediators - fatty acid ethanolamides (FAEs) and epoxidized fatty acids (EpFAs), respectively - which are biogenetically distinct but share the ability to attenuate pain responses and inflammation. In these experiments, we evaluated the antihyperalgesic activity of small-molecule inhibitors of FAAH and sEH, administered alone or in combination, in two pain models: carrageenan-induced hyperalgesia in mice and streptozocin-induced allodynia in rats. When administered separately, the sEH inhibitor 1-trifluoromethoxyphenyl-3-(1-propionylpiperidine-4-yl)urea (TPPU) and the peripherally restricted FAAH inhibitor URB937 were highly active in the two models. The combination TPPU plus URB937 was markedly synergistic, as assessed using isobolographic analyses. The results of these experiments reveal the existence of a possible functional crosstalk between FAEs and EpFAs in regulating pain responses. Additionally, the results suggest that combinations of sEH and FAAH inhibitors might be exploited therapeutically to achieve greater analgesic efficacy.

Graphical Abstract
1. Introduction

Various bioactive lipid mediators regulate nociceptive pain and inflammation in peripheral tissues by interacting with receptor systems on primary sensory neurons and neighboring host-defense cells, such as macrophages, mast cells and keratinocytes [1]. In this context, two classes of long-chain fatty acid derivatives have been studied with particular attention: the fatty acid ethanolamides (FAE) [1] and the epoxidized fatty acids (EpFAs) [2,3]. These lipids demonstrate marked analgesic and anti-inflammatory properties but are subject to rapid deactivating metabolism, with the primary route for both being enzymatic hydrolysis [1–3]. The FAEs are degraded primarily by fatty acid amide hydrolase (FAAH) while the EpFAs are metabolized by soluble epoxide hydrolase (sEH). Both enzymes are hydrolases, but they are in different protein families. Because of the roles of the FAE and EpFAs in pain modulation [1] FAAH and sEH have been intensely studied to develop pharmacological inhibitors that are able to sustain endogenous levels of these analgesic and anti-inflammatory mediators.

FAAH is an intracellular serine hydrolase that belongs to the amide signature hydrolase superfamily of enzymes [4,5]. Preferred FAAH substrates include endogenous agonists of cannabinoid receptors, such as anandamide (arachidonylethanolamide) [6,7], and type-α peroxisome proliferator-activated receptors (PPAR-α), such as oleoylethanolamide (OEA) [8] and palmitolethanolamide (PEA) [9]. sEH is a bifunctional enzyme with an N-terminal phosphatase activity, whose physiological function is unclear, and a C-terminal hydrolase activity that catalyzes the conversion of EpFAs into dihydroxy fatty acids [10]. The epoxide hydrolase domain of sEH belongs to the α/β-hydrolase fold family of proteins [11]. Most of the activity of sEH is attributed to this domain, because EpFAs are known to activate large-conductance potassium (BK) channels [12], nuclear receptors (e.g. PPAR-α and PPAR-γ) [13,14], transient receptor potential (TRP) channels [15–17] as well as to inhibit the pro-inflammatory transcription factor NF-κB [18,19]. While there is evidence for the existence of EpFA receptors [20,21], the identities of these putative receptors remain undefined [22]. By contrast, the endocannabinoid anandamide is a known agonist of two G protein-coupled receptors, namely the CB₁ and CB₂ cannabinoid receptors [23]. Interestingly, the epoxyeicosatrienoic acids (EETs) weakly displace radioligand binding at CB₂, but not CB₁.
receptors [24]. The significance of this weak CB\textsubscript{2} agonism remains to be determined, but it is of interest due to the suggested role of CB\textsubscript{2} receptors in peripheral pain modulation [25]. Little is known about the interaction of EpFAs derived from n-3 polyunsaturated fatty acids (e.g., docosahexaenoic acid and eicosapentaenoic acid) with the endocannabinoid system. However, EETs and n-3 EpFAs are robustly antihyperalgesic in acute and chronic models of pain [26,27]. The fact that EETs, as a subset, do not significantly activate the endocannabinoid receptor system suggests EpFAs and FAEs act through complementary rather than overlapping mechanisms.

Preclinical studies have documented the anti-inflammatory and anti-hyperalgesic effects of FAAH [1] and sEH inhibitors [3]. In the present study, we asked whether these two classes of agents act in an additive or super-additive (synergistic) manner to attenuate pain responses in rodent models. We used the peripherally restricted FAAH inhibitor URB937, which has no access to the brain and spinal cord yet causes pronounced antihyperalgesic effects that are due to its ability to elevate anandamide levels outside the brain and spinal cord [28]. sEH blockade was achieved employing the potent inhibitor 1-trifluoromethoxyphenyl-3-(1-propionylpiperidine-4-yl)urea (TPPU) [29]. As experimental models, we utilized a mouse model of acute inflammation (carrageenan) and a rat model of neuropathy (insulin-dependent diabetes evoked by streptozocin).

2. Materials and methods

2.1 Animals

We used male CD1 mice (25 to 30 g; Charles River, Calco, Italy) and Sprague–Dawley male rats (250 to 300 g; Charles River, Wilmington, MA, USA). All procedures performed in Italy were in accordance with the Ethical Guidelines of the International Association for the Study of Pain, Italian regulations on the protection of animals used for experimental and other scientific purposes (D.M. 116192), and European Economic Community regulations (O.J. of E.C. L 358/1 12/18/1986). Procedures and animal care performed at the University of California, Davis adhered to the guidelines of the National Institutes of Health guide for the care and use of Laboratory animals and were performed in accordance with the protocols approved by the Animal Use and Care Committee (IACUC) of the University of California, Davis. Great care was taken to minimize suffering of the animals and to reduce the number of animals used. Mice were housed in groups of 5 in ventilated cages containing autoclaved cellulose paper as nesting material and rats were housed 2 per cage on corncob bedding all with free access to food and water. They were maintained under a 12 h light/dark cycle (lights on at 08:00 a.m.), at controlled temperature (21 ± 1 °C) and relative humidity (55 ± 10%). The animals were randomly divided in groups of 6. Behavioral testing was performed between 9:00 a.m. and 5:00 p.m. Scientists running the experiments were not aware of the treatment protocol at the time of the test (blind procedure).

2.2 Chemicals

\(\lambda\)-Carrageenan, PEG 400 and TWEEN 80, were purchased from Sigma–Aldrich (Milan, Italy). The sEH inhibitors TPPU, 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea, \(t\)-TUCB, \(trans\)-4-[4-(3-trifluoromethoxyphenyl-l-ureido)-cyclohexyloxy]-benzoic acid
and the FAAH inhibitor URB937,3-(3-carbamoylphenyl)-4-hydroxy-phenyl] N-cyclohexylcarbamate, were synthesized and characterized in house as previously described [30–32]. URB937 was prepared immediately before use in 80% sterile saline solution/10% PEG 400/10% Tween 80 and orally administered to mice in a volume of 2.5 mL kg⁻¹.

TPPU, t-TUCB and URB937 administered to rats were prepared immediately before use in PEG 400 and intraperitoneally administered in a volume of 1 mL kg⁻¹.

2.3 Carrageenan-induced inflammation

We induced paw edema by injecting λ-carrageenan (1% weight/vol in sterile water, 50 μL) into the left hind paw of lightly restrained adult male CD1 mice. Edema was measured with a plethysmometer (Ugo Basile, Comerio, Italy). Fresh inhibitor solutions were prepared immediately before use in 80% sterile saline solution/10% PEG-400/10% Tween 80 and orally administered in a volume of 2.5 mL kg⁻¹. All experiments were performed in a quiet room, and experimenters were blinded to the treatment protocol at the time of the test. Mechanical hyperalgesia was evaluated by measuring the latency (in s) to withdraw the paw from a constant mechanical pressure exerted onto the dorsal surface [31]. A 15-g calibrated glass cylinder (diameter = 10 mm) drawn to conical point (diameter = 3 mm) was used to exert the mechanical force. The weight was suspended vertically between two rings attached to a stand and was free to move vertically. A cutoff time of 180 s was used. Heat hyperalgesia was assessed by the method of Hargreaves et al. [33], measuring the latency to withdraw the hind paw from a focused beam of radiant heat (thermal intensity: infrared 3.0) applied to the plantar surface in a plantar test apparatus (Ugo Basile). The cutoff time was set at 30 s.

2.4 Diabetic neuropathic pain model

Diabetic neuropathic pain was modeled using streptozocin, an antibiotic that selectively destroys pancreatic beta cells. The decrease in mechanical withdrawal thresholds (MWTs) measured with the von Frey assay (IITC, Woodland Hills, CA) develops within 5–7 days after streptozocin administration and persists for the lifetime of the animal. Baseline naive MWTs were established prior to induction of diabetes. For this, rats were acclimated to the laboratory and apparatus for 1 h and MWT were probed at least three times at 1-min intervals; the scores averaged per animal. After naive MWTs were assessed, streptozocin (55 mg kg⁻¹) in saline was injected via the tail vein as previously reported [34]. After one week, the MWTs of diabetic rats were measured and allodynia (a painful response to innocuous stimulation) was confirmed. Rats that scored 65% or lower of the original naive baseline were considered allodynic and included in the experimental groups. For the bioassay, rats were assessed for their diabetic neuropathic MWTs and then injected intraperitoneally (i.p.) with TPPU or URB937 and MWT were measured 30, 60, 90, 120, 150, and 180 min after the injection. The procedure was followed for all doses (0.03, 0.1, 0.3, 1, 3 mg kg⁻¹) of TPPU, 3 mg kg⁻¹ t-TUCB and (0.03, 0.1, 0.3, 1, 3 mg kg⁻¹) URB937. The diabetic neuropathic pain baselines and subsequent MWTs are reported as grams of force needed to elicit hind paw withdrawal.
2.5 Isobolographic analyses

The interaction between TPPU and URB937 was characterized by isobolographic analysis assuming that the combinations were constituted by equally effective doses of the individual drugs. Thus, from the dose–response curves of each individual agent, the median effective dose (ED$_{50}$) was determined at time point of 4 hours in the carrageenan model and 1 hour in the diabetic neuropathic pain model. The ED$_{50}$ were plotted on the x- and y-axes. Subsequently, dose–response curves were obtained by concurrent delivery of both drugs (URB937 and TPPU) in fixed ratios, based on the ED$_{50}$ values of each individual agent in the four different measurements. To construct this curve, groups of animals received one dose of one of the following combinations: (1) (URB937 ED$_{50}$ + TPPU ED$_{50}$); (2) (URB937 ED$_{50}$ + TPPU ED$_{50}$)/2; (3) (URB937 ED$_{50}$ + TPPU ED$_{50}$)/4; or (4) (URB937 ED$_{50}$ + TPPU ED$_{50}$)/8. The experimental ED$_{50}$ value for the combination was calculated from each curve at time point of 4 hours in the carrageenan model and 1 hour in the diabetic neuropathic pain model. The theoretical additive ED$_{50}$ was estimated from the dose–response curve of each drug administered individually, which presupposes that the observed effect of the combination is the sum of the effects of each individual drug. This theoretical ED$_{50}$ value was then compared with the experimentally derived ED$_{50}$ value to determine if there was a statistically significant difference [35–37]. Drug combinations producing pharmacological synergism with potentiation generate experimental points that fall below the line joining the two axes corresponding to the theoretical additive line (isobole). Conversely, drug combinations producing antagonism generate experimental points that fall above the isobole.

2.6 In vitro inhibition assay

For the recombinant human (hsEH), mouse (msEH) and rat (rsEH) sEH, the in vitro IC$_{50}$ values were determined using a previously reported fluorescence method using cyano(2-methoxynaphthalen-6-yl)methyl(3-phenyloxiran-2-yl)methyl carbonate (CMNPC) as substrate [38]. The recombinant sEHs were incubated with the inhibitors for 5 min in 100 mM sodium phosphate buffer (200 μL; pH 7.4) at 30 °C before fluorescent substrate (CMNPC) introduction ([S] = 5 μM). The rates of formation of the fluorescent product were assessed and were linear for the duration of the assay. It has been previously demonstrated that the sEHI IC$_{50}$ values obtained with the fluorescence assay correlate extremely well (linear correlation coefficient R$^2$=0.9) with the natural substrate (14,15 EET per a LC–MS method)[39]. For the recombinant human FAAH (hFAAH), N-(6-methoxypyridin-3-yl)octanamide ([S]= 50 μM) was used as substrate as previously described [40]. The enzyme was incubated in sodium phosphate buffer (0.1 M pH 8.0) containing 0.1 mg/mL of BSA for 5 min with the inhibitor before substrate introduction. The activity was followed kinetically for 10 min at 30C by following the appearance of the fluorescent product. The 2-AG-activity was measured in rat brain microsomes using a colorimetric assay as previously described [41].

2.7 Statistical analyses

Results are expressed as the mean ± SEM, or 95% confidence limits (95% CL). Effective doses were determined by linear regression analysis of dose–response curves. Individual
slopes of the dose–response curves were compared by Student’s t-test, according to the test of parallelism, and isobolographic analyses were performed using the Prism software (GraphPad Software, San Diego, CA). The data from mechanical and heat hyperalgesia and mechanical allodynia were compared using two-way analysis of variance (ANOVA) followed by Bonferroni’s test for multiple comparisons.

3. Results

3.1 Antihyperalgesic effects of TPPU, URB937 and synergy in a model of acute inflammation

To evaluate the antihyperalgesic activity of TPPU, which has not been previously reported, we tested the compound in the carrageenan model of acute inflammation in CD1 mice. Oral administration of the compound (0.1–10 mg kg\(^{-1}\)) produced a dose-dependent and persistent suppression of carrageenan-induced edema (Fig. 1A). When TPPU was administered at its highest dosage (10 mg kg\(^{-1}\)), the effect was still statistically detectable 24 hours after application (Fig. 1A, P< .001). The median effective dose (ED\(_{50}\)) for TPPU was 0.3 mg kg\(^{-1}\) (CL 95% = 0.0087–0.13 mg kg\(^{-1}\)). The CD1 mouse model was used previously to evaluate antihyperalgesic effects of FAAH inhibitors including URB937, whose ED\(_{50}\) on edema was 0.5 mg kg\(^{-1}\) (Fig. 1B) (CL 95% = 0.038–0.47 mg kg\(^{-1}\)) \([31]\). The sEH inhibitor and FAAH inhibitor were also effective against mechanical hyperalgesia (Fig. 1C–D), and heat hyperalgesia (Fig. 1E–F). On mechanical hyperalgesia, the ED\(_{50}\) value for TPPU was 1 mg kg\(^{-1}\) (CL 95% = 0.032–0.55 mg kg\(^{-1}\)) and for URB937 was 0.8 mg kg\(^{-1}\) (CL 95% = 0.021–0.43 mg kg\(^{-1}\)); on heat hyperalgesia the ED\(_{50}\) for TPPU was 0.5 mg kg\(^{-1}\) (CL 95% = 0.049–0.51 mg kg\(^{-1}\)) and for URB937 was 0.2 mg kg\(^{-1}\) (CL 95% = 0.058–0.46 mg kg\(^{-1}\)). To assess possible anti-hyperalgesic synergy with coadministration of sEH and FAAH inhibitors, we investigated the effects of combinations of TPPU plus URB937 (Fig. 2). Co-administration of TPPU and URB937 in four oral fixed ratios resulted in dose- and time-dependent anti-inflammatory effects in the carrageenan model (Fig. 2C and E). The isobolographic analysis of the data supported that TPPU and URB937 acted synergistically against both types of hyperalgesia (Fig. 2D and F). The results suggest that TPPU prevents both edema and the development of acute pain responses evoked by carrageenan in mice. Additionally, TPPU and URB937 act synergistically to attenuate acute pain-related responses evoked by carrageenan.

3.2 Inhibitor efficacy and synergy in a model of chronic neuropathic pain

We next tested whether TPPU and URB937 are able to alleviate the mechanical allodynia associated with a diabetic neuropathic pain model. We produced peripheral neuropathy in rats using streptozocin, which results in the development of allodynia (Fig. 3). We administered TPPU (0.03–3 mg kg\(^{-1}\)) intraperitoneally to diabetic rats and measured mechanical allodynia. As shown in Fig. 3A, a single administration of TPPU was sufficient to cause a rapid reversal of established allodynia (P < 0.001 for 3 mg kg\(^{-1}\)). The TPPU ED\(_{50}\) was 0.1 mg kg\(^{-1}\) (CL 95% = 0.053–0.11 mg kg\(^{-1}\)). Figure 3B shows that the peripheral FAAH inhibitor URB937 also inhibited mechanical allodynia in diabetic rats, with an ED\(_{50}\) of 0.3 mg kg\(^{-1}\) (CL 95% = 0.064–0.43 mg kg\(^{-1}\)). The average naïve baseline for groups that were induced for the diabetic model was 78.6±0.9 SEM grams to elicit a withdrawal. This
value declined with the diabetic neuropathy to a diabetic baseline of 45.2±0.7 SEM. However with the 3 mg kg\(^{-1}\) i.p. dose of TPPU the pre diabetic average was met at the 60 and 90 minute time points (77.7±1.1 and 79.4±2.7 grams respectively). Lower doses of TPPU were significant in elevating thresholds over the diabetic baselines, though did not meet naïve baselines. The effects of TPPU and URB937 (3 mg kg\(^{-1}\)) were similar to those of another sEH inhibitor, \(t\)-TUCB (3 mg kg\(^{-1}\)i.p., Fig. 3C), which previously demonstrated efficacy in the diabetic neuropathy model [42]. Thus, two structurally distinct sEH inhibitors produced potent antihyperalgesia in this chronic pain model. Interestingly, the duration of action of \(t\)-TUCB was greater than those of TPPU or URB937 (Fig. 3C). However, because of the \textit{in vitro} selectivity of the individual inhibitors on sEH and FAAH (Table I), TPPU was selected for co-administration with the FAAH inhibitor to probe for synergistic effects \textit{in vivo}. When TPPU and URB937 were administered together, the combination displayed improved efficacy over the time course of the diabetic neuropathy model (Fig. 4A). An isobolographic analysis of the data shows that TPPU and URB937 were robustly synergistic (Fig. 4B).

4. Discussion

In this study we determined the effect of combining a FAAH inhibitor with a sEH inhibitor in two rodent models of pain: carrageenan-induced hyperalgesia in mice and streptozocin-induced allodynia in rats. Our rationale was to enhance the concentration and thus the effective activity of the lipid mediators that are degraded by these enzymes (namely, FAE by FAAH and EpFAs by sEH), which are known to produce analgesic effects through independent mechanisms. Thus, we hypothesize that these mediators are synergistic at the physiological level. The results show that FAAH and sEH inhibitors are individually active, as previously demonstrated [31,42], and that their activity is synergistically enhanced by co-administration. This synergy may be exploited therapeutically to achieve better pain control at lower drug dosages or to develop dual agents that simultaneously inhibit both FAAH and sEH activities.

sEH inhibitors (sEHI) such as \(t\)-TUCB have demonstrated anti-hyperalgesic activity in the streptozocin model, both in rats and mice, and in clinical equine laminitis, a chronic neuropathy with inflammatory origins [42–44]. In the present study we tested the compound TPPU, which had not been tested in pain models before, for several reasons: (1) it is highly potent (Ki = 0.91 nM) [45] and selective for sEH over FAAH (Table 1); (2) it has improved water solubility (60 μg/ml) and lower melting point (198.2 C) compared to other sEHI; and (3) has a longer \(k_{off}\) rate on recombinant human sEH, as assessed by FRET displacement [45]. TPPU is a competitive, tight-binding reversible inhibitor more potent than sEHI previously shown to elevate both plasma and tissue (including nervous tissue) levels of epoxy fatty acids with concurrent improvement of nociceptive thresholds [42,46]. Our results show that TPPU is highly effective in reducing mechanical and heat hyperalgesia evoked by carrageenan (Fig. 1), and attenuating allodynia in the rat streptozocin model (Fig. 3).

The kinetically irreversible peripheral FAAH inhibitor URB937 was previously tested in the mouse carrageenan model [31]. In those experiments, URB937 showed efficacy at 0.3 mg
kg$^{-1}$ in reducing paw volume and increasing thermal and mechanical paw withdrawal latencies. The same study also tested URB937 in a sciatic nerve constriction model of neuropathy, where the compound also successfully elevated withdrawal thresholds. Multiple FAAH inhibitors and specifically URB937 has been shown to elevate anandamide in vivo [28]. Here, the 0.3 mg kg$^{-1}$ dose of URB937 attenuated allodynia in neuropathic rats (Fig. 3B). The efficacy of URB937 in the constriction injury model of neuropathy in mice was similar to the results in the diabetic neuropathy model in rat [31]. However, the duration of the effect of URB937 and TPPU may have been affected by the induced drug metabolizing enzyme activity in the streptozocin model [46].

The combination of URB937 and TPPU showed significant synergistic efficacy in the two pain models investigated here (Figures 2 and 4). sEH blockade is known to synergize with other inhibitors targeting the arachidonic acid cascade. The improved nociceptive outcome with co-administration of cyclooxygenase (COX) inhibitors was an early demonstration of this effect [47,48]. Administration of sEH correlates with a decrease in COX-2 protein and mRNA expression levels [49,50]. In fact, combining indomethacin, a COX inhibitor, with either FAAH or sEH inhibitors revealed synergy in inflammatory pain models [31,47]. Given the demonstrated effect of COX in metabolizing endocannabinoids [51,52] and the potential for the prostamide metabolites of COX to increase neuronal excitability [53], it is possible that this mechanism contributed to the synergy of combined FAAH and sEH inhibitors. There has been recent exploration of selective COX-2 inhibitors that block prostamide production but leave prostaglandins intact [54]. However, the sEH mediated down regulation of induced COX-2 mRNA data are from spinal cord whereas URB937 is peripherally restricted, so there is likely a combined beneficial effect on the nociceptive endpoints. Despite this, the sEH inhibition can alter COX-2 protein in liver [49], a major site of metabolism, and therefore there may be a COX-2 related mechanism when TPPU is combined with the peripherally restricted FAAH inhibitor. Future studies will investigate the benefits of a strategy to combine inhibitors of all three of these enzymes the FAAH, sEH and COX in either a polypharmacological approach or with a designed multiple ligand molecule.

Alternatively, recent studies have addressed possible crosstalk between the cannabinoid and cytochrome P450 pathways exemplified by the epoxygenation of endocannabinoids. In experiments using human liver microsomes arachidonoylethanolamide (anandamide) was transformed in vitro into all four possible regioisomers of epoxidized eicosatrienoic ethanolamide (EET-EA) metabolites [55]. These metabolites were further transformed by epoxide hydrolase into their corresponding diols. The EET-EA metabolites were also formed in human brain microsomal and mitochondrial preparations [56]. Biologically, it was found that the EET-EA metabolites had low nanomolar IC$_{50}$ on the CB$_2$ receptors and specifically 5,6-EET-EA was more stable in mouse brain and had a higher affinity at the CB$_2$ receptor than anandamide. Use of a sEH inhibitor in this study demonstrated that sEH was primarily responsible for the degradation of the EET-EA product and not FAAH [57]. Additionally, Chen et al. identified two epoxygenated arachidonyl glycerol regioisomers, 2-11,12-EG and 2-14,15-EG, that were produced in vivo. Both regioisomers of 2-EG bind to CB$_1$ and CB$_2$ receptors with slightly improved potency over 2-AG [58]. Thus, there is a
possibility that blocking the degradation of the FAE with FAAH inhibitors in combination with sEH inhibitors elevates several classes of metabolites that cooperate to elicit antihyperalgesic and antiinflammatory effects. In future experiments it will be important to define the site of action of the putative metabolites and their relative concentrations as well as the in vivo efficacy.

5. Conclusion

The antihyperalgesic effects of FAE and EpFA are evident with in vivo inhibition of their principal degrading enzymes: FAAH and sEH respectively. This activity is observable in two distinct models of pain including acute inflammatory and diabetic neuropathic pain employed here. Moreover, coadministration of these enzyme inhibitors results in a synergistic reduction in pain behavior. These results are suggestive of a crosstalk between these lipid-derived signaling pathways.

Acknowledgments

Research Funding: This study was partially supported by grants from the National Institutes on Drug Abuse (RO1-DA-012413, DP1DA031387 to D.P.). The work completed at the University of California Davis was supported by the National Institute of Environmental Health Sciences (NIEHS) Grant R01 ES002710, NIEHS Superfund Research Program P42 ES004699, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) R21AR062866, National Institute of Neurological Disorders and Stroke (NINDS) U54 NS079202-01 and Grants NIEHS T32ES007059 and NIH 5T32DC008072-05 (to K.W.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. B.D.H. is a George and Judy Marcus Senior Fellow of the American Asthma Foundation.

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BK</td>
<td>large-conductance potassium channels</td>
</tr>
<tr>
<td>CB</td>
<td>cannabinoid receptor</td>
</tr>
<tr>
<td>CL</td>
<td>confidence limits</td>
</tr>
<tr>
<td>ED_{50}</td>
<td>median effective dose</td>
</tr>
<tr>
<td>EpFA</td>
<td>epoxidized fatty acids</td>
</tr>
<tr>
<td>FAAH</td>
<td>fatty-acid amide hydrolase</td>
</tr>
<tr>
<td>FAE</td>
<td>fatty acid ethanolamides</td>
</tr>
<tr>
<td>OEA</td>
<td>oleoylethanolamide</td>
</tr>
<tr>
<td>PEA</td>
<td>palmitoylethanolamide</td>
</tr>
<tr>
<td>PPARα and PPARγ</td>
<td>peroxisome proliferator-activated receptors</td>
</tr>
<tr>
<td>sEH</td>
<td>soluble epoxide hydrolase</td>
</tr>
</tbody>
</table>

References


Pharmacol Res. Author manuscript; available in PMC 2016 July 01.


Pharmacol Res. Author manuscript; available in PMC 2016 July 01.


TPPU and URB937 show antiedematogenic and antihyperalgesic effects in a carrageenan model of acute inflammation in mice. (A) TPPU (0.1–10 mg kg\(^{-1}\), oral) and (B) URB937 (0.1–3 mg kg\(^{-1}\), oral) produced a robust reduction in paw volume. The two inhibitors reduced mechanical (C–D) and heat (E–F) hyperalgesia. The compounds were administered orally before intraplantar injection of carrageenan. Paw volume, mechanical and heat hyperalgesia were measured before (0 h) or 2, 4, 6, 24 and 48 h after TPPU (0.3–10 mg kg\(^{-1}\)) and URB937 (0.1–3 mg kg\(^{-1}\)) administration and were significantly different compared to vehicle treated groups. Results are expressed as mean ± SEM (n=6, each group). The data were compared using two-way analysis of variance (ANOVA) followed by Bonferroni’s test for multiple comparisons. * p<0.05, ** p< 0.01 and *** p<0.001 vs. vehicle.
Figure 2.
TPPU synergizes with URB937 in reducing paw volume, mechanical and heat hyperalgesia. (A, C and E) Combinations in fixed ratios of TPPU with URB937 produce a decrease of paw volume and a reduction of mechanical and heat hyperalgesia in dose- and time-dependent manner. Paw volume, mechanical and heat hyperalgesia were measured immediately before (0 h) or 2, 4, 6, 24 and 48 h after the combination. (B, D and F) The synergy was supported by an isobolographic analysis that revealed a substantial difference in the experimental value below the isobole which indicates pharmacological synergism with potentiation. Results are expressed as mean ± SEM (n=6, each group). The data were compared using two-way analysis of variance (ANOVA) followed by Bonferroni’s test for multiple comparisons. * P<0.05, ** P< 0.01 and *** P<0.001 vs. vehicle.
Figure 3.
TPPU and URB937 in single administration reduce diabetic neuropathic pain in rat. (A) The TPPU dose dependent reduction of allodynia was highly significant in diabetic neuropathic rats (P ≤0.001 0.1–3 mg kg$^{-1}$). (B) URB937 also significantly improved mechanical withdrawal thresholds in neuropathic rats (P ≤0.05 0.1 mg kg$^{-1}$, P ≤0.001 0.3–3 mg kg$^{-1}$).

The average naïve baseline for groups that were induced for the diabetic model was 78.6±0.9 SEM grams of force to elicit a withdrawal. This value declined with the diabetic neuropathy to a diabetic baseline of 45.2±0.7 SEM. The withdrawal data were compared using two-way analysis of variance (ANOVA) followed by Bonferroni’s test for multiple comparisons.
comparisons. (C) The 3 mg·kg⁻¹ doses of TPPU and URB937 are compared with the sEH inhibitor t-TUCB. The sEH inhibition showed similar efficacy at the same dose with two structurally diverse small molecule inhibitors in the chronic pain model. Results are expressed as mean ± SEM (n=6, each group). The data were compared using two-way analysis of variance (ANOVA) followed by Bonferroni’s test for multiple comparisons. * P<0.05, ** P< 0.01 and *** P<0.001 vs. vehicle.
Figure 4. TPPU synergizes with URB937 against diabetic neuropathic pain in rat. (A) The combinations of URB937 and TPPU effectively blocked allodynia in the diabetic neuropathy model. The combination of the inhibitors in one i.p. administration was more efficacious (P ≤0.001) than vehicle over several hours. (B) The isobolographic analysis of the URB937 and TPPU combination supports the efficacy is synergistic against chronic neuropathic pain. Filled circles represent the theoretical ED$_{50}$ with 95% confidence limits (CL). Open circles the experimental ED$_{50}$ with 95% CL. Results are expressed as mean ± SEM (n=6, each group). These groups are included in the average scores for pre-diabetic (78.6±0.9 SEM grams) and pretreatment diabetic (45.2±0.7 SEM grams) baselines. Results are expressed as mean ± SEM (n=6, each group). The data were compared using two-way analysis of variance (ANOVA) followed by Bonferroni’s test for multiple comparisons. ** $P<0.01$ and *** $P<0.001$ vs. vehicle.
Table I

Comparative *in vitro* efficacy of FAAH and sEH inhibitors

<table>
<thead>
<tr>
<th>Structure</th>
<th><em>h</em>FAAH</th>
<th><em>h</em>sEH</th>
<th><em>m</em>sEH</th>
<th><em>r</em>sEH</th>
<th>2-AG hydrolysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>FAAH</td>
<td>17 ± 4</td>
<td>7,180 ± 550</td>
<td>17,800 ± 1,200</td>
<td>16,600 ± 1,200</td>
<td>&gt;100,000</td>
</tr>
<tr>
<td>URB937</td>
<td>6,610 ± 880</td>
<td>0.9 ± 0.2</td>
<td>7.4 ± 1.0</td>
<td>4.6 ± 0.4</td>
<td>&gt;100,000</td>
</tr>
<tr>
<td>sEH</td>
<td>260 ± 80</td>
<td>0.4 ± 0.1</td>
<td>3.1 ± 0.8</td>
<td>11.9 ± 1.8</td>
<td>&gt;100,000</td>
</tr>
</tbody>
</table>

The IC₅₀ of URB937 on the FAAH enzyme was previously determined to be 26.8 ± 4.9 nM in rat. The median inhibitory activity of URB937 on non-target monoacylglycerol lipase (MAGL) was >100 nM in mice [28]. The results presented in the table are (n=3) averages ± standard deviation with differences of 2-fold or greater considered significant [40].